Allergy

Angkeow discusses a recent study finding that PhIP-Seq analysis links diverse IgG responses to food allergy phenotypes.

Su discussed the role of delabeling non-narcotic analgesic allergy labels in obstetrics care.

In this Q&A, Fleischer discusses clinically meaningful gains in peanut allergy desensitization, strong response rates, and the path toward FDA submission for VP250.

Phase 3 VITESSE data show VIASKIN peanut patch improves tolerance in most children, with high adherence and a favorable safety profile.

Shamji shared the factors influencing which treatments are best for each patient and further research he'd like to see.

Su described how NNAALs drive management decisions in pregnancy and post partum care.

High costs, limited insurance coverage, and adherence challenges remain key barriers to broader SLIT use in the US, Larenas-Linnemann says in an interview at AAAAI 2026.

Investigational RNA interference therapy targeting prekallikrein enters accelerated regulatory pathway as phase 2 trial evaluates long-acting prophylaxis for HAE.

The FDA has set a PDUFA date of December 30, 2026.

At AAAAI 2026, Anna Nowak-Wegrzyn, MD, discussed the use of ondansetron, home management strategies, and guidance on the gradual reintroduction of foods in FPIES.

Research presented at AAAAI 2026 found that 88% of participants preferred intranasal epinephrine over injectables.

Data presented at AAAAI 2026 showed that adding dupilumab to omalizumab-facilitated oral immunotherapy improved desensitization and reduced gastrointestinal adverse events.

Wood discussed the potential of BTK inhibition for peanut allergy and beyond.

This HCPLive Five captures 5 interviews conducted on-site at AAAAI 2026.

Wood discussed factors that go into shared decision making for multi-food allergy.

At AAAAI 2026, DiGiacomo discussed how artificial intelligence, genetic testing, and biomarkers could improve diagnosis and precision care.

McWilliam discussed findings from the TreEat study at AAAAI 2026.

At AAAAI 2026, Torres highlighted phase 3 peach immunotherapy research, nanostructure preclinical models, and a phase 2 prebiotic trial for LTP allergy.

At AAAAI 2026, Magerl discusses phase 2 data showing BW-20805 reduced hereditary angioedema attacks by up to 100% with dosing intervals of up to 6 months.

Wood discussed the latest long term data from OUtMATCHat AAAAI 2026.

At AAAAI 2026, Larenas-Linnemann discusses evidence, safety, and long-term benefits of sublingual immunotherapy for allergic rhinitis and asthma.

At AAAAI 2026, Nowak-Wegrzyn presented FPIES diagnosis in infants, emphasizing clinical recognition and updated oral food challenge protocols.

Stay updated with the latest healthcare breakthroughs, FDA actions, and new trial data, in this week’s essential news roundup.

Phase 2 ALPHA-SOLAR data presented at AAAAI 2026 show navenibart provides >95% median attack reduction in HAE with favorable safety for 3- and 6-month prophylaxis.